Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against CancerYong Gu Lee, Marco Ruella, Jakub Svoboda et al.|Cancer Discovery|2022Cited by 98
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomasGuido Ghilardi, Stephen J. Schuster, Elise A. Chong et al.|Annals of Oncology|2022Cited by 95
CD5 deletion enhances the antitumor activity of adoptive T cell therapiesRuchi P. Patel, Patrizia Porazzi, Guido Ghilardi et al.|Science Immunology|2024Cited by 45
The BTLA–HVEM axis restricts CAR T cell efficacy in cancerPuneeth Guruprasad, Marco Ruella, Alberto Carturan et al.|Nature Immunology|2024Cited by 41
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokinesGuido Ghilardi, Marco Ruella, Luca Paruzzo et al.|Blood Advances|2023Cited by 30